# Anti-CD38 Antibody Treating APS With Thrombocytopenia

> **NCT05983952** · PHASE2 · RECRUITING · sponsor: **Institute of Hematology & Blood Diseases Hospital, China** · enrollment: 10 (estimated)

## Conditions studied

- Antiphospholipid Syndrome
- Thrombocytopenia

## Interventions

- **DRUG:** Anti-CD38 antibody Injection

## Key facts

- **NCT ID:** NCT05983952
- **Lead sponsor:** Institute of Hematology & Blood Diseases Hospital, China
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-08-01
- **Primary completion:** 2025-08
- **Final completion:** 2025-08
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2025-08-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05983952

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05983952, "Anti-CD38 Antibody Treating APS With Thrombocytopenia". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT05983952. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*